Opsumit Fails to Improve Cardiac Function or Prevent Fluid Retention

Viewing 0 reply threads
  • Author
    • #11053
      Kathleen Sheffer

      Results published by the European Respiratory Journal in February 2018 reported Opsumit (Macitentan) failed to achieve the goals of a Phase 2 clinical trial over a 12-week period. Researchers concluded that patients treated with Opsumit were “quantitatively more likely to experience significant fluid retention versus placebo” and that the drug had no significant impact on the patients’ heart function. (Read more).

      The FDA approved Opsumit for PH patients in 2013. Are you on this therapy? Did you participate in the trial? What symptoms do you experience?

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2022 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account

Verify you are not a robot